New data at the biochemical, genetic, and molecular levels have indicated in recent years the association of osteogenesis imperfecta (OI) with various mutations in the genes (COLlAl and COLIA2) which encode for type I procollagen. 1 2 The striking clinical heterogeneity3 of brittle bone disease is emphasised by the molecular data which have been accumulating in the last three years; each mutation studied so far is a different one. They occur sporadically in the severest cases, while they are transmitted in an autosomal dominant fashion in milder cases. Mutations which cause structural abnormalities ofproal(I) and proa2(I) chains are more commonly found in severe variants of 01 and can often be shown by the biochemical analysis of collagen I. Methods DNA was prepared from peripheral blood, digested with the appropriate restriction endonuclease, electrophoresed on agarose gels, transferred to Hybond C filters, and hybridised with probes which had been labelled with 32P by multiprimer directed synthesis. Hybridisation conditions were as previously described. " Segregation of COLlAl and COL1A2 was analysed in the pedigrees by means of three restriction site polymorphisms for each locus, as previously described. 1 " The following RFLPs were used:
FG2IMspI, 2FC6/RsaI, and NST70/RsaI for COL IA 1, and NJ3IEcoRI, Hf32/RsaI, and Hf32IMspI for COL1A2. Table 1 shows the eight possible RFLP haplotype combinations at the COLlAl and COL1A2 loci; these haplotype numbers are used in the pedigree representations. Lod score analysis was performed with the M-LINK program.'4 In some cases, fibroblasts were grown by standard methods from skin biopsies obtained from affected subjects and Electrophoretic analysis of collagens obtained from skin fibroblasts of at least one or more affected members from families 1, 2, 3, and 7 showed no structural alteration. Preliminary data on collagen type I mRNA levels in family 1 indicate a decrease in proul(I) mRNAs compared to normal controls (subject III.6). 
